Prothena Plc Financials

PRTA Stock  USD 14.15  0.40  2.75%   
Based on the measurements of operating efficiency obtained from Prothena Plc's historical financial statements, Prothena plc may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, Prothena Plc's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 59.7 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 35.1 M. Key indicators impacting Prothena Plc's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.00190.002
Notably Down
Slightly volatile
Current Ratio22.3311.237
Way Up
Very volatile
The essential information of the day-to-day investment outlook for Prothena Plc includes many different criteria found on its balance sheet. An individual investor should monitor Prothena Plc's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Prothena Plc.

Net Income

(139.68 Million)

  
Please note, the presentation of Prothena Plc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prothena Plc's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prothena Plc's management manipulating its earnings.

Prothena Plc Stock Summary

Prothena Plc competes with Equillium, DiaMedica Therapeutics, Valneva SE, Vivani Medical, and Denali Therapeutics. Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company was founded in 2012 and is based in Dublin, Ireland. Prothena Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINIE00B91XRN20
CUSIPG72800108
LocationIreland
Business Address77 Sir John
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.prothena.com
Phone353 1 236 2500
CurrencyUSD - US Dollar

Prothena Plc Key Financial Ratios

Prothena Plc Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets419.3M333.0M609.4M758.0M696.4M414.8M
Other Current Liab6.8M10.7M10.2M16.5M29.3M30.7M
Accounts Payable1.2M4.1M3.7M9.3M25.4M26.7M
Other Assets13.7M31.1M10.4M30.9M35.6M37.3M
Total Liab146.3M149.0M143.3M136.0M135.0M89.0M
Other Current Assets2.7M3.9M10.7M15.6M15.3M16.1M
Total Current Assets378.4M299.3M584.8M719.1M639.3M410.5M
Net Debt(352.8M)(277.5M)(566.8M)(703.9M)(607.0M)(576.6M)
Retained Earnings(671.9M)(783.0M)(716.1M)(833.0M)(980.0M)(931.0M)
Cash375.7M295.4M579.1M710.4M618.8M437.9M
Net Receivables68K15K13K62K5.2M5.4M
Net Tangible Assets272.9M184.0M466.0M622.0M715.3M381.1M
Capital Surpluse920.6M944.4M966.6M1.2B1.4B801.6M
Short Term Debt5.1M11.0M11.9M12.9M2.2M2.1M

Prothena Plc Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense8.2M8.3M6.7M6.7M7.7M8.1M
Total Revenue814K853K200.6M53.9M91.4M95.9M
Gross Profit(50.0M)853K200.6M53.9M(129.2M)(122.7M)
Operating Income(85.7M)(112.7M)72.0M(131.6M)(191.0M)(181.5M)
Ebit(85.7M)(112.7M)72.0M(131.6M)(191.0M)(181.5M)
Research Development50.8M74.9M82.3M135.6M220.6M231.6M
Ebitda(85.8M)(105.8M)78.8M(130.8M)(190.1M)(180.6M)
Cost Of Revenue50.8M74.9M82.3M6.7M220.6M231.6M
Income Before Tax(77.3M)(111.4M)71.9M(125.6M)(160.5M)(152.5M)
Net Income(77.7M)(111.1M)67.0M(116.9M)(147.0M)(139.7M)
Income Tax Expense379K(283K)4.9M(8.7M)(13.5M)(12.8M)
Tax Provision379K(283K)4.9M(8.7M)(13.5M)(12.8M)
Interest Income8.2M1.4M42K6.3M31.0M32.6M
Net Interest Income8.2M1.4M42K6.3M31.0M32.6M

Prothena Plc Key Cash Accounts

201920202021202220232024 (projected)
Free Cash Flow(53.5M)(80.6M)92.0M(109.3M)(136.7M)(129.9M)
Depreciation6.8M7.0M6.8M744K928K881.6K
Capital Expenditures555K196K575K464K2.8M1.9M
Net Income(77.7M)(111.1M)67.0M(116.9M)(147.0M)(139.7M)
Change To Inventory(396.2M)9.6M(10.3M)(8.9M)(10.2M)(10.7M)
Change In Cash(53.3M)(80.3M)282.4M132.2M(91.6M)(87.0M)
End Period Cash Flow378.4M298.1M580.4M712.6M621.0M440.1M
Change Receivables(62K)238K53K15K17.3K16.4K
Other Non Cash Items37.3M28.2M38.7M6.0M7.5M12.0M
Change To Netincome(1.2M)(1.7M)4.6M20.2M23.2M24.4M
Investments(547K)(196K)(575K)(464K)(1.4M)(1.5M)

Prothena Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Prothena Plc's current stock value. Our valuation model uses many indicators to compare Prothena Plc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prothena Plc competition to find correlations between indicators driving Prothena Plc's intrinsic value. More Info.
Prothena plc is regarded fourth in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . At present, Prothena Plc's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Prothena Plc's earnings, one of the primary drivers of an investment's value.

Prothena plc Systematic Risk

Prothena Plc's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Prothena Plc volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Prothena plc correlated with the market. If Beta is less than 0 Prothena Plc generally moves in the opposite direction as compared to the market. If Prothena Plc Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Prothena plc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Prothena Plc is generally in the same direction as the market. If Beta > 1 Prothena Plc moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Prothena Plc Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Prothena Plc's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Prothena Plc growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(1.06)

At present, Prothena Plc's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

Prothena Plc December 11, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Prothena Plc help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Prothena plc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Prothena plc based on widely used predictive technical indicators. In general, we focus on analyzing Prothena Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Prothena Plc's daily price indicators and compare them against related drivers.

Complementary Tools for Prothena Stock analysis

When running Prothena Plc's price analysis, check to measure Prothena Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prothena Plc is operating at the current time. Most of Prothena Plc's value examination focuses on studying past and present price action to predict the probability of Prothena Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prothena Plc's price. Additionally, you may evaluate how the addition of Prothena Plc to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities